Debiopharm
Private Company
Funding information not available
Overview
Debiopharm is a 45-year-old, privately held biopharmaceutical company based in Lausanne, Switzerland, employing approximately 420 people. It operates a hybrid business model combining proprietary drug development in oncology and infectious diseases with contract manufacturing and venture investment in digital health. The company's pipeline features a range of novel modalities, including antibody-drug conjugates (ADCs), small molecule inhibitors, and peptides, targeting various hallmarks of cancer. With a history of successful drug launches and a focus on enabling future standards of care, Debiopharm positions itself as a specialized developer and strategic partner in the life sciences ecosystem.
Technology Platform
Multilink™ ADC platform, synthetic peptide development, small molecule DNA damage response inhibitors, integrated GMP manufacturing capabilities, and a digital health investment fund for strategic scouting.
Opportunities
Risk Factors
Competitive Landscape
Debiopharm competes in the highly competitive oncology field against large pharmaceutical companies and biotechs with substantial resources, particularly in the DNA damage response and ADC spaces. Its differentiation lies in its specialized development expertise, integrated manufacturing, and a capital-efficient partnership model rather than direct commercial competition.